Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.43−1.68 (-1.57%)
Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –
Edwards Lifesciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Edwards Lifesciences's revenue for the twelve months ending Jun 30, 2026 was $6.51B, up 14.6% year over year. For fiscal 2025 it was $6.07B, up 11.5% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $6.07B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.07B | +11.5% |
| FY2024 | Dec 31, 2024 | $5.44B | +8.6% |
| FY2023 | Dec 31, 2023 | $5.01B | +12.2% |
| FY2022 | Dec 31, 2022 | $4.46B | -14.7% |
| FY2021 | Dec 31, 2021 | $5.23B | +19.3% |
| FY2020 | Dec 31, 2020 | $4.39B | +0.9% |
| FY2019 | Dec 31, 2019 | $4.35B | +16.8% |
| FY2018 | Dec 31, 2018 | $3.72B | +8.4% |
| FY2017 | Dec 31, 2017 | $3.44B | +15.9% |
| FY2016 | Dec 31, 2016 | $2.96B | +18.8% |
| FY2015 | Dec 31, 2015 | $2.49B | +7.4% |
| FY2014 | Dec 31, 2014 | $2.32B | +13.6% |
| FY2013 | Dec 31, 2013 | $2.05B | +7.7% |
| FY2012 | Dec 31, 2012 | $1.90B | +13.2% |
| FY2011 | Dec 31, 2011 | $1.68B | +16.0% |
| FY2010 | Dec 31, 2010 | $1.45B | +9.5% |
| FY2009 | Dec 31, 2009 | $1.32B | +6.8% |
| FY2008 | Dec 31, 2008 | $1.24B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.74B | +13.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.65B | +16.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.57B | +13.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.55B | +14.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.53B | +11.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.41B | +6.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.39B | +9.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.35B | +8.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.37B | +7.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.33B | +8.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.27B | +194.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.24B | -5.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.28B | -6.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.22B | -8.9% |
| Q4 FY2022 | Dec 31, 2022 | $429.90M | -67.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.32B | +0.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.37B | -0.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.34B | +10.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.33B | +11.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.31B | +14.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.38B | +48.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.22B | +7.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.19B | +1.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.14B | +4.3% |
| Q2 FY2020 | Jun 30, 2020 | $925.00M | -14.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.13B | +13.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.17B | +20.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.09B | +20.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.09B | +15.2% |
| Q1 FY2019 | Mar 31, 2019 | $993.00M | +11.0% |
| Q4 FY2018 | Dec 31, 2018 | $977.70M | +10.0% |
| Q3 FY2018 | Sep 30, 2018 | $906.60M | +10.4% |
| Q2 FY2018 | Jun 30, 2018 | $943.70M | +12.1% |
| Q1 FY2018 | Mar 31, 2018 | $894.80M | +1.3% |
| Q4 FY2017 | Dec 31, 2017 | $888.50M | +15.7% |
| Q3 FY2017 | Sep 30, 2017 | $821.50M | +11.1% |
| Q2 FY2017 | Jun 30, 2017 | $841.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $883.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $767.70M | – |
| Q3 FY2016 | Sep 30, 2016 | $739.40M | – |
See a number that looks wrong?